In short
Clinical trials are studying Ly3473329 in adults with elevated lipoprotein(a), also called Lp(a), who are at high risk for cardiovascular events. These trials mainly look at safety and how well the treatment works. The main study in the data is a Phase 2 trial in adult participants.
Key points
- Clinical trial data for Ly3473329 focus on adults with elevated lipoprotein(a), also called Lp(a), who are at high risk for cardiovascular events. The main study is a Phase 2 interventional trial and it has been completed. It included 233 participants and compared Ly3473329 with a matching placebo. The main result measured was the percent change in Lp(a) from the start of the study to Week 12. Overall, the trial was designed to assess both safety and how well Ly3473329 works in this patient group.
Trial overview
The main clinical trial in the data studied Ly3473329 in adults with elevated lipoprotein(a), also written as Lp(a), who were at high risk for cardiovascular events. The study was designed to evaluate both efficacy and safety, meaning it looked at whether the treatment helped and whether it could be used safely in the study group.
Who was studied
The trial focused on adult participants with elevated Lp(a). These participants were also described as being at high risk for cardiovascular events, which means they had a greater chance of serious heart or blood vessel problems.
Study design and treatment groups
This was an interventional study, so participants received a study treatment rather than only being observed. The listed interventions included Ly3473329 at 240 mg taken orally and a placebo made to match Ly3473329. A placebo is a look-alike treatment with no active medicine, used so researchers can compare results fairly.
What was measured
The main outcome was the percent change from baseline in Lp(a) from the start of the study to Week 12. Baseline means the first measurement before treatment begins, and percent change shows how much the level went up or down over time. This endpoint helps researchers see whether Ly3473329 changes Lp(a) levels in the study participants.
Trial status and size
The trial status is listed as Completed. A total of 233 people were enrolled, which means 233 participants joined the study. The study was a Phase 2 trial, a stage that usually looks more closely at whether a treatment works while continuing safety checks.
What this means for patients
For patients, this trial is important because it targets a blood marker, Lp(a), that is linked to cardiovascular risk. The study was not a general health study; it was focused on adults with a specific lipoprotein disorder and higher heart risk. The results were planned to show whether Ly3473329 could lower Lp(a) over 12 weeks in this group.